Targeted Next-Generation Sequencing (NGS) panels are increasingly being used to discover causative variants for inherited cancer, such as Hereditary Breast and Ovarian Cancer. As such panels continue to expand there is a growing demand for multiplexed reference materials that cover a broad range of pathogenic variants to expedite test development and validation. The traditional practice of using reference materials from public biobanks or remnant patient samples with single pathogenic variants can be extremely time consuming and expensive. The alternative is to use reference materials broadly characterized by whole genome sequencing, but these generally contain few, if any, clinically representative variants in commonly tested genes.

Seraseq Inherited Cancer DNA Mix v1 addresses the lack of multiplexed reference materials for targeted NGS assays with an expert-designed product¹ (and published methodology²) focused on seven genes associated with inherited cancer including BRCA1 and BRCA2. This unique product combines over 20 variants in a well-characterized genomic background that can be used for assay development and analytical validation.

• Expedite assay development and validation with ready source of over 20 inherited cancer specific variants
• Save $1000s in sequencing and validation costs with a highly multiplexed configuration
• Assess common, rare as well as technically challenging variants
• Well-characterized GM24385 human genomic DNA as background \"wild-type” material
• Manufactured in GMP-compliant and ISO 13485-certified facilities
• Customizable to cover desired variants (from pre-defined library or user-defined)

Target genes covered:

• BRCA1
• BRCA2
• MSH6
• MSH2
• MLH1
• PMS2
• CDKN2A

List of mutations incorporated: See Package Insert for more information

For research use only. Not for use in diagnostic procedures.

>>> 更多资讯详情请访问蚂蚁淘商城